Axsome Therapeutics Target Price

See Axsome Therapeutics's analyst price targets ($290) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$186.14

Average Target Price

$289.91

55.7% upside

11 analysts in the last 4 months

High: $380 | Low: $247

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-25	Morgan Stanley	$247	32.7% upside
2026-09-23	Truist FinancialSrikripa Devarakonda	$285	53.1% upside
2026-08-12	Mizuho SecuritiesGraig Suvannavejh	$316	69.8% upside
2026-08-11	RBC CapitalLeonid Timashev	$297	59.6% upside
2026-08-11	Wells Fargo	$256	37.5% upside
2026-08-11	Guggenheim	$275	47.7% upside
2026-08-11	NeedhamAmi Fadia	$268	44% upside
2026-08-11	Morgan Stanley	$251	34.8% upside
2026-07-20	BMO CapitalMalcolm Hoffman	$310	66.5% upside
2026-07-07	RBC CapitalLeonid Timashev	$304	63.3% upside
2026-06-11	JefferiesAndrew Tsai	$380	104.1% upside
2026-05-05	H.C. Wainwright	$290	55.8% upside
2026-05-05	Robert W. BairdBrian Skorney	$246	32.2% upside
2026-05-05	Deutsche BankDavid Hoang	$280	50.4% upside
2026-05-05	Morgan Stanley	$242	30% upside
2026-05-05	Needham	$267	43.4% upside
2026-05-05	RBC CapitalLeonid Timashev	$302	62.2% upside
2026-05-04	Oppenheimer	$280	50.4% upside
2026-05-04	Piper Sandler	$258	38.6% upside
2026-05-04	GuggenheimYatin Suneja	$260	39.7% upside
2026-05-04	H.C. WainwrightRaghuram Selvaraju	$270	45.1% upside
2026-05-04	Deutsche BankDavid Hoang	$281	51% upside
2026-05-04	JefferiesAndrew Tsai	$275	47.7% upside
2026-05-04	Cantor Fitzgerald	$272	46.1% upside
2026-05-01	Oppenheimer	$250	34.3% upside
2026-04-30	Morgan Stanley	$217	16.6% upside
2026-04-10	UBS	$259	39.1% upside
2026-02-24	UBS	$251	34.8% upside
2026-02-24	RBC Capital	$222	19.3% upside
2026-02-24	Morgan Stanley	$207	11.2% upside
2026-02-24	Guggenheim	$220	18.2% upside
2026-02-24	Wells Fargo	$202	8.5% upside
2026-02-23	Wolfe ResearchRudy Li	$230	23.6% upside
2026-02-23	Truist FinancialJoon Lee	$200	7.4% upside
2026-02-23	Jefferies	$215	15.5% upside
2026-02-19	Mizuho Securities	$230	23.6% upside
2026-01-21	RBC CapitalLeonid Timashev	$219	17.7% upside
2026-01-20	H.C. Wainwright	$260	39.7% upside
2026-01-16	Piper Sandler	$223	19.8% upside
2026-01-13	Wells Fargo	$193	3.7% upside
2026-01-13	Robert W. Baird	$209	12.3% upside
2026-01-08	Morgan Stanley	$204	9.6% upside
2026-01-06	UBS	$248	33.2% upside
2026-01-05	NeedhamAmi Fadia	$225	20.9% upside
2026-01-05	H.C. WainwrightRaghuram Selvaraju	$200	7.4% upside
2026-01-02	GuggenheimYatin Suneja	$205	10.1% upside
2025-12-31	Mizuho SecuritiesGraig Suvannavejh	$217	16.6% upside
2025-12-31	OppenheimerJay Olson	$220	18.2% upside
2025-11-04	H.C. Wainwright	$185	0.6% downside
2025-11-04	RBC Capital	$198	6.4% upside

Axsome Therapeutics (AXSM) FAQ

As of the most recent data, AXSM shows a target price of $290. Scroll down for historical charts and peer comparison views.

If Axsome Therapeutics moved to the average analyst target of $290, shares would be roughly 55.7% higher than $186.14. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Axsome Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Axsome Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $290) with ownership activity and broader fundamentals.

Axsome Therapeutics's target price is $290; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.